Immunoconjugates with optimized linkers and orientation

Patent metadata

Field	Value
Publication number	US-2020165326-A1
Application number	US-201816487991-A
Country	US
Kind code	A1
Filing date	Feb 20, 2018
Priority date	Feb 24, 2017
Publication date	May 28, 2020
Grant date	—

Abstract

The present invention relates to fusion proteins comprising a growth factor linked to the N-terminus of an antibody via a linker peptide, in particular, wherein said growth factor iS IGF-1 and said antibody is directed against collagen.

First claim

1 . Fusion protein comprising
an antibody, or a fragment or derivative thereof retaining target binding properties, and an insulin-like growth factor 1 (IGF-1), wherein said antibody, or fragment or derivative thereof, and said growth factor are linked by a peptide linker, wherein the peptide linker is fused to the N-terminus of at least one peptide chain of the antibody, or the fragment or derivative thereof.

2 . Fusion protein according to claim 1 , wherein said antibody, or fragment or derivative thereof, is specifically binding to a collagen.

3 . Fusion protein according to claim 1 , wherein said antibody, or fragment or derivative thereof, is capable of binding both collagen I and collagen II.

4 . (canceled)

5 . The fusion protein according to claim 1 , wherein said antibody is a monoclonal antibody selected from any of the group consisting of hybridoma-derived, chimerized, humanized or human antibody.

6 . The fusion protein according to claim 1 , wherein said antibody is a monoclonal antibody selected from any of the group consisting of canine or caninized antibody, and/or equine or equinized antibody.

7 . The fusion protein according to claim 1 , wherein the antibody is in at least one format selected from the group consisting of
IgG and diabody.

8 . The fusion protein according to claim 1 ,
wherein the linker comprises an amino acid sequence selected from any of the group consisting of

a)

(SEQ ID NO: 10)

GGGAKGGGGKAGGGS

b)

(SEQ ID NO: 11)

GGGGDGGGGDGGGGS

c)

(SEQ ID NO: 12)

GSADGGSSAGGSDAG

d)

(SEQ ID NO: 13)

GGGGSGGGGEGGGGS,

and

e)

(SEQ ID NO: 14)

GGGGSGGGGSGGGGS.

9 . The fusion protein according to claim 1 , wherein said antibody has the following CDRs

VL-CDR1
SEQ ID NO: 1

VL-CDR2
SEQ ID NO: 2

VL-CDR3
SEQ ID NO: 3

VH-CDR1
SEQ ID NO: 4

VH-CDR2
SEQ ID NO: 5

VH-CDR3
SEQ ID NO: 6.

10 . The fusion protein according to claim 1 , wherein said antibody has light chain variable domain (VL) domain according to SEQ ID NO: 7 and a heavy chain variable domain (VH) domain according to SEQ ID NO: 8.

11 . (canceled)

12 . The fusion protein according to claim 1 , wherein said fusion protein is a recombinant fusion protein.

13 . The fusion protein according to claim 1 , which fusion protein comprises at least one chain comprising the amino acid sequence of SEQ ID NO: 15.

14 . The fusion protein according to claim 1 , which fusion protein comprises at least one chain comprising the amino acid sequence of SEQ ID NO: 16.

15 . The fusion protein according to claim 1 , which fusion protein comprises at least one chain comprising the amino acid sequence of SEQ ID NO: 17.

16 . The fusion protein according to claim 1 , which fusion protein comprises at least one chain comprising the amino acid sequence of SEQ ID NO: 18.

17 . The fusion protein according to claim 1 , which fusion protein comprises at least one chain comprising the amino acid sequence of SEQ ID NO: 19.

18 . The fusion protein according to claim 1 , which fusion protein comprises at least one chain comprising the amino acid sequence of SEQ ID NO: 20.

19 - 23 . (canceled)

24 . A method of treating a human or animal subject which is suffering from, at risk of developing, or diagnosed for
(a) arthritis, preferentially osteoarthritis, or (b) ligament or tendon injury, which method comprises administering to said subject a fusion protein according to claim 1 .

25 . (canceled)

26 . The method according to claim 24 , wherein the fusion protein is administered by an intra-articular injection.

27 . An ex vivo method of pre-treatment of ligaments or tendons used for reparative surgery, which method comprises incubating a ligament or tendon with a fusion protein according to claim 1 .

Assignees

• Philogen Spa

Inventors

• Wulhfard Sarah
• Matasci Mattia

Classifications

• C07K19/00

  Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes} · CPC title

• A61K47/6813

  the drug being a peptidic cytokine, e.g. an interleukin or interferon · CPC title

• C07K16/18 Primary

  against material from animals or humans · CPC title

• C07K2319/00

  Fusion polypeptide · CPC title

• C07K14/65 Primary

  Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2 · CPC title